A Phase I Study of the Adam-10 Inhibitor, INCB7839 in Children With Recurrent/Progressive High-Grade Gliomas to Target Microenvironmental Neuroligin-3
Latest Information Update: 26 Feb 2025
Price :
$35 *
At a glance
- Drugs Aderbasib (Primary)
- Indications Anaplastic astrocytoma; Diffuse intrinsic pontine glioma; Glioblastoma; Glioma; Oligodendroglioma
- Focus Adverse reactions; Pharmacokinetics
- 19 Feb 2025 Status changed from active, no longer recruiting to completed.
- 15 Nov 2024 Planned End Date changed from 30 Jun 2024 to 31 Mar 2025.
- 11 May 2023 Status changed from recruiting to active, no longer recruiting.